Abstract:Background Tigecycline, the first glycylcycline-class drug, is a broad-spectrum antibiotic with activity against multi-drug resistant (MDR) organisms. We describe a case of sustained and severe hypoglycemia in a patient treated with tigecycline for pneumonia due to MDR Klebsiella pneumoniae. Case presentation A 74-year-old man was admitted for treatment of pneumonia. At admission he had prediabetes. In the hospital he developed renal failure. On day 3, the patient experienced severe shortness of breath. He was intubated and transferred to the intensive care unit (ICU) for ventilator support. In the ICU the antibiotic regimen was cefoperazone and sulbactam (1 g every 12 h). Continuous Renal Replacement Therapy was started on that day. Test for anti-neutrophil cytoplasmic antibodies (ANCA) was positive, and so the nephrologist and rheumatologist agreed on a diagnosis of ANCA-associated vasculitis, with renal and pulmonary involvement and acute renal failure. Plasmapheresis, and high-dose methylprednisolone treatment were started on day 6, and there was obvious improvement in the patient's condition. The steroid regimen was gradually tapered to oral prednisone (35 mg every day) on day 19. Afterwards, the patient's pneumonia worsened. Sputum culture showed Klebsiella pneumoniae sensitive to only tigecycline. Tigecycline treatment (100 mg every 12 h) was administered on day 20. Hypoglycemia started about 37 h after the first dose of tigecycline. Infusion of 50% glucose through the femoral vein was required for over 20 h to maintain normal blood glucose concentrations. Tigecycline was stopped, but the hypoglycemia resolved only after a further 34 h. The insulin and C-peptide levels were found to be markedly elevated during the hypoglycemia. The Naranjo scale score of 7 indicated that the likelihood of tigecycline causing severe hypoglycemia was "probable." Conclusion This is the first report of sustained severe hypoglycemia due to tigecycline. Oversecretion of insulin appears to have been the cause of the hypoglycemia in our patient. The mechanism needs to be investigated.

One Case of Rhabdomyolysis Induced by Moxifloxacin and Literature Review

Rhabdomyolysis related to moxifloxacin in two patients

Lomefloxacin-induced Hypoglycemia in an Elderly Patient with Chronic Kidney Disease:A Case Report

Polymyxin B-induced Rhabdomyolysis

Rhabdomyolysis Associated With Febuxostat in a Non-Chronic Kidney Disease (CKD) Patient: Diagnostic and Management Challenges

QT interval prolongation and type I hypersensitivity reaction caused by orally taken moxifloxacin

Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration

Moxifloxacin Induced Liver Injury by Causing Lachnospiraceae Deficiency and Interfering with Butyric Acid Production through Gut–Liver Axis

Literature Analysis of Moxifloxacin-induced Adverse Drugs Reactions in 3 445 Cases

A Case Report of Rhabdomyolysis Caused by the Use of Roxadustat in the Treatment of Caused by Renal Anemia

A Case Report of Rhabdomyolysis Caused by the Use of Roxadustat in the Treatment Caused by Renal Anaemia

Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

Rhabdomyolysis Causing Renal Failure Following Cardiopulmonary Resuscitation, Cardioversion, and Myocardial Infarction: A Case Report and Review of the Literature

A case report on the rhabdomyolysis caused by the interaction of simvastatin

Tigecycline-induced Sustained Severe Hypoglycemia: a Case Report

Causative Study of Drug-induced Rhabdomyolysis

Rhabdomyolysis syndrome associated with a single dose of ursodexoycholic acid

Venlafaxine-Associated Rhabdomyolysis

Simvastatin-induced rhabdomyolysis

MDMA("Ecstasy") abuse leading to delayed onset rhabdomyolysis: A case report and literature review

Case Report: Etoposide-nedaplatin induced rhabdomyolysis in a small cell lung cancer patient